全球瞩目的2025年欧洲肿瘤内科学会年会（ESMO Congress 2025）将于10月17日至21日在德国柏林盛大召开。
7月25日，ESMO官网已公布了除LBA之外的常规摘要题目及讲者信息。【肿瘤资讯】特此整理了中枢神经系统肿瘤领域入选优选口头报告（Proffered Paper Session）与迷你口头报告（Mini Oral Session）的重磅临床研究，带您一睹前沿风采。
优选口头报告
656O
Title：Proton versus Carbon Ion Radiotherapy in Skull Base Chordoma and Chondrosarcoma: Initial Clinical Outcomes from a Phase II Randomized Trial
标题：质子与碳离子放射治疗颅底脊索瘤和软骨肉瘤：一项II期随机试验的初步临床结果
讲者：Huang Qingting (Shanghai, China)
657O
Title：A randomized, controlled, multicenter, phase II/III clinical study to evaluate the safety and efficacy of chlorogenic acid for injection in the treatment of recurrent grade IV glioblastoma (GBM)
标题：一项评估注射用绿原酸治疗复发性IV级胶质母细胞瘤（GBM）安全性和有效性的随机、对照、多中心II/III期临床研究
讲者：李文斌 (中国北京，首都医科大学附属北京天坛医院)
658O
Title：Nivolumab, ipilimumab and bevacizumab together with 2 cycles of induction chemotherapy in patients with non-squamous NSCLC and untreated brain metastases (CA209-7WF / Break B5-BM-NSCLC / AIO-TRK-0220/ass)
标题：纳武利尤单抗、伊匹木单抗和贝伐珠单抗联合2个周期的诱导化疗用于非鳞状非小细胞肺癌（NSCLC）且未经治疗的脑转移（BM）患者（CA209-7WF / Break B5-BM-NSCLC / AIO-TRK-0220/ass）
讲者：Daniel Heudobler (Regensburg, Germany)
659O
Title：Molecular diagnosis and management of leptomeningeal metastases with evolving therapeutic paradigm in advanced lung cancer
标题：晚期肺癌软脑膜转移的分子诊断与管理及不断演变的治疗模式
讲者：郑媚美 (中国广州，广东省人民医院)
迷你口头报告
660MO
Title：A phase 1, first-in-human study of regorafenib plus temozolomide with or without radiotherapy in patients with newly diagnosed MGMT methylated, IDH wildtype glioblastoma: the REGOMA-2 trial
标题：一项瑞戈非尼联合替莫唑胺加或不加放疗治疗新诊断MGMT甲基化、IDH野生型胶质母细胞瘤患者的1期首次人体研究：REGOMA-2试验
讲者：Marta Padovan (Padua, Italy)
661MO
Title：Update on the phase II study: to explore the efficacy and safety of luvometinib (FCN-159) in recurrent or progressive pediatric low-grade glioma with MAPK pathway-activated
标题：探索luvometinib（FCN-159）在复发性或进展性、MAPK通路激活的儿童低级别胶质瘤中的疗效和安全性的II期研究进展
讲者：李文斌 (中国北京，首都医科大学附属北京天坛医院)
662MO
Title：Phase 1/2a study of concomitant radiotherapy with olaparib and temozolomide (TMZ) in unresectable high-grade gliomas patients (pts) – Results from the phase 2a (OLA-TMZ-RTE-01)
标题：奥拉帕利和替莫唑胺（TMZ）同步放疗在不可切除高级别胶质瘤患者（pts）中的1/2a期研究——2a期（OLA-TMZ-RTE-01）结果
讲者：DInu STEFAN (Caen, France)
663MO
Title：Phase I trial of an IL13Rα2-targeted CAR-T cell therapy for recurrent malignant glioma: clinical results and pharmacokinetics
标题：IL13Rα2靶向CAR-T细胞疗法治疗复发性恶性胶质瘤的I期试验：临床结果和药代动力学
讲者：Ho-Shin Gwak (Goyang, Republic of Korea)
664MO
Title：Long-term efficacy and safety of larotrectinib in TRK fusion primary central nervous system tumours: an updated analysis
标题：拉罗替尼在TRK融合原发性中枢神经系统肿瘤中的长期疗效和安全性：一项更新分析
讲者：Lorena Valero-Arrese (Barcelona, Spain)
665MO
Title：DNA methylation-based epigenetic signatures for classification and non-invasive diagnosis of gliomas
标题：基于DNA甲基化的表观遗传特征用于神经胶质瘤的分类和无创诊断
讲者：王郑封 (中国郑州，郑州大学第一附属医院)
666MO
Title：Reliability of Cerebrospinal Fluid (CSF) ctDNA as a Surrogate for Tumor Mutational Profiling in Central Nervous System (CNS) Metastases: Results from the BrainStorm (OncoDistinct006) Study
标题：脑脊液（CSF）循环肿瘤DNA（ctDNA）作为中枢神经系统（CNS）转移瘤肿瘤突变分析替代物的可靠性：BrainStorm（OncoDistinct006）研究结果
讲者：Luca Arecco (Genova, Italy)
ESMO官网
排版编辑：肿瘤资讯-丹忱
苏公网安备32059002004080号
